STING-Targeting Gene Therapy for SAVI Treatment
Summary
The University of Florida Research Foundation has filed a patent application (US20260109741A1) for nucleic acids containing dominant negative STING alleles designed to treat STING-associated vasculopathy with onset in infancy (SAVI), a rare autoimmune condition. The application, filed October 22, 2025, covers both the compositions and methods for delivering these gene therapy constructs to human subjects with STING-mediated diseases. Inventor Lei Jin developed the dominant negative STING allele approach to suppress aberrant STING signaling that drives SAVI pathology.
“Provided herein are nucleic acids containing dominant negative STING alleles and compositions containing the same.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
USPTO published patent application US20260109741A1, filed by the University of Florida Research Foundation on October 22, 2025, covering dominant negative STING alleles and compositions for treating STING-associated vasculopathy with onset in infancy (SAVI). The application claims nucleic acid constructs and methods for delivering these dominant negative STING alleles to human subjects suffering from STING-mediated conditions or diseases.
For biotechnology and pharmaceutical companies developing gene therapies targeting rare autoimmune or inflammatory diseases, this patent positions the University of Florida in the STING pathway modulation space. Companies researching similar approaches to STING-associated diseases should consider freedom-to-operate analysis and potential licensing discussions with the University of Florida Research Foundation.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
STING-TARGETING GENE THERAPY
Application US20260109741A1 Kind: A1 Apr 23, 2026
Assignee
University of Florida Research Foundation, Incorporated
Inventors
Lei Jin
Abstract
Provided herein are nucleic acids containing dominant negative STING alleles and compositions containing the same. Further provided are methods of using the nucleic acids containing dominant negative STING alleles for treating STING-associated vasculopathy with onset in infancy (SAVI). Also provided are methods of delivering the nucleic acids containing dominant negative STING alleles to treat STING-mediated conditions or diseases in human subjects in need thereof.
CPC Classifications
C07K 14/47 A61P 37/00 C12N 15/86
Filing Date
2025-10-22
Application No.
19365352
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.